Skip to main content

Show 46 results Show all

Self-injected subcutaneous DMPA: A new frontier in advancing contraceptive access and use for women

This brief details the strong body of evidence and experience with self-injection of DMPA-SC in low-resource settings, including how the practice can reduce access-related barriers, improve contraceptive continuation, and enhance women’s autonomy.

Institutional Author(s): PATH
Publication date: October, 2019

Resources: A list of references about subcutaneous DMPA

This brief lists key references and resources from the evidence base on DMPA-SC. Pair this with the Evidence at-a-glance brief if your target decision-maker would like to have access to the data in that handout.

Institutional Author(s): PATH
Publication date: October, 2019

An overview of subcutaneous DMPA: A new type of injectable contraception that expands access and options

This brief offers quick facts on the benefits of DMPA-SC; the product’s potential for empowering women and adolescent girls; the product’s availability; and how subcutaneous DMPA is different from intramuscular DMPA (DMPA-IM).

Institutional Author(s): PATH
Publication date: October, 2019

Advocacy pack for subcutaneous DMPA: Tools for advocacy and communications to increase access to a new type of injectable contraception

Subcutaneous DMPA (DMPA-SC) is an innovative and easy-to-use injectable that is transforming contraceptive access, use, and choice for women and adolescent girls. Advocates have an important role to play in making sure their country’s policies and funding support access to a broad method mix, including new options like DMPA-SC.

The Advocacy Pack for Subcutaneous DMPA is designed to accelerate your advocacy efforts. It consists of evidence-based materials, in English and French, for advocates to use both for their own strategy development and for direct advocacy with decision-makers. Materials are customizable and unbranded so that you can tailor them to your country context.

Institutional Author(s): PATH
Publication date: October, 2019

Collaboration helps broaden access to Pfizer’s contraceptive, Sayana® Press (medroxyprogesterone acetate)

This press release announces the price reduction of Sayana Press from $1 to $0.85 per dose in qualifying countries.

Institutional Author(s): Pfizer, Inc.
Publication date: May, 2017

Brief Collaboration helps broaden access to Pfizer’s contraceptive, Sayana® Press (medroxyprogesterone acetate)

WHO Selected practice recommendations for contraceptive use

Along with WHO’s Medical eligibility criteria for contraceptive use, this is one of two evidence-based guidance documents of the WHO’s initiative to develop and implement family planning guidelines for national programs. This document provides guidance for how to use contraceptive methods safely and effectively once they are deemed to be medically appropriate. Safety considerations include common barriers to safe, correct and consistent use of contraception and the benefits of preventing unintended or unwanted pregnancy.

Institutional Author(s): World Health Organization (WHO)
Publication date: June, 2016

Guide Web page

Medical Eligibility Criteria for Contraceptive Use

The MEC provides guidance to national family planning and reproductive health programmes in the preparation of guidelines for the delivery of contraceptive services. The guide provides information on the safety and use of intramuscular and subcutaneous DMPA.

Institutional Author(s): World Health Organization (WHO)
Publication date: August, 2015

Guide Web page

Results 4 Informed Choice

Results 4 Informed Choice is a resource for HIV and family planning program implementers, government representatives, advocates and journalists as they respond to the results from the Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial.

The trial results, released June 13, 2019, showed that none of the three contraceptive methods in the trial increased the risk of HIV acquisition. Other findings, including high HIV incidence across the study arms and broad acceptability and effectiveness of the contraceptive methods, are a call to action for greater attention to and investment in women’s health, HIV prevention and contraceptive choice. Full findings from the study can be found in the Lancet article.

The tools, resources and data are intended to help stakeholders plan and execute their response so that women have all the information they need to make an informed choice in adopting and using a contraceptive method and protecting themselves from HIV.

Institutional Author(s): Johns Hopkins Center for Communication Programs (JHU CCP)
Publication date: 2022

Tool Link to Website

Introducing new self-care family planning methods: Lessons from DMPA-SC and the Caya diaphragm

This webinar held on February 23, 2022 was hosted by Expanding Effective Contraceptive Options (EECO) led by WCG Cares with PSI and the DMPA-SC Access Collaborative led by PATH in partnership with JSI. The discussion focused on the introduction and scale up of self-care family planning methods in sub-Saharan Africa, highlighting lessons and best practices from DMPA-SC scale-up and Caya® diaphragm pilot introductions in French-speaking West Africa. Presenters from Benin, Niger, and Senegal shared successes and challenges. This webinar was offered in French.

Institutional Author(s): PATH, JSI, Inc., Population Services International (PSI), Association Béninoise pour le Marketing Social et la Communication pour la Santé, Expanding Effective Contraceptive Options
Publication date: February, 2022

Pharmacies and Drug Shops: Expanding contraceptive choice and access in the private sector

Expanding access to contraceptive methods through the private sector and community-based sources—which includes task sharing—is an important strategy to help achieve national family planning and development goals and, in particular, aims to reduce barriers to access for youth, lower-income, and other marginalized groups. Private sector pharmacies and drug shops are often the first line of health care in low- and middle-income countries, particularly for many underserved populations and especially in rural areas that have very few private or public clinics. While there are differences between pharmacies and drug shops, there are also common issues around implementation and impact. For both, training and support can improve and expand the range and quality of services they offer and thereby increase access and choice for women.

Institutional Author(s): High Impact Practices in Family Planning (HIPs)
Publication date: August, 2021